The estimated Net Worth of Robert Z Gussin is at least $550 Tisíc dollars as of 1 May 2023. Robert Gussin owns over 9,284 units of Cassava Sciences Inc stock worth over $483,577 and over the last 10 years he sold SAVA stock worth over $0. In addition, he makes $66,744 as Independent Director at Cassava Sciences Inc.
Sign up
Robert Gussin SAVA stock SEC Form 4 insiders trading
Robert has made over 3 trades of the Cassava Sciences Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 9,284 units of SAVA stock worth $165,162 on 1 May 2023.
The largest trade he's ever made was exercising 9,284 units of Cassava Sciences Inc stock on 1 May 2023 worth over $165,162. On average, Robert trades about 1,222 units every 37 days since 2014. As of 1 May 2023 he still owns at least 17,694 units of Cassava Sciences Inc stock.
You can see the complete history of Robert Gussin stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert Gussin biography
Dr. Robert Z. Gussin Ph.D. serves as Independent Director of the Company. Dr. Gussin worked at Johnson & Johnson for 26 years, most recently as Chief Scientific Officer and Corporate Vice President, Science and Technology from 1986 through his retirement in 2000. Dr. Gussin served on the board of directors of Duquesne University and the advisory boards of the Duquesne University Pharmacy School and the University of Michigan Medical School Department of Pharmacology. Dr. Gussin received his B.S. and M.S. degrees and D.Sc. with honors from Duquesne University and his Ph.D. in Pharmacology from the University of Michigan, Ann Arbor.
What is the salary of Robert Gussin?
As the Independent Director of Cassava Sciences Inc, the total compensation of Robert Gussin at Cassava Sciences Inc is $66,744. There are 6 executives at Cassava Sciences Inc getting paid more, with Remi Barbier having the highest compensation of $1,073,230.
How old is Robert Gussin?
Robert Gussin is 82, he's been the Independent Director of Cassava Sciences Inc since 2003. There are 1 older and 8 younger executives at Cassava Sciences Inc. The oldest executive at Cassava Sciences Inc is Sanford Robertson, 88, who is the Independent Director.
What's Robert Gussin's mailing address?
Robert's mailing address filed with the SEC is 6801 N CAPITAL OF TEXAS HWY, BLDG 1, SUITE 300, AUSTIN, TX, 78731.
Insiders trading at Cassava Sciences Inc
Over the last 6 years, insiders at Cassava Sciences Inc have traded over $0 worth of Cassava Sciences Inc stock and bought 1,178,376 units worth $9,853,781 . The most active insiders traders include Sanford Robertson, Richard Barry a Patrick J Md Phd Scannon. On average, Cassava Sciences Inc executives and independent directors trade stock every 45 days with the average trade being worth of $1,235,207. The most recent stock trade was executed by Sanford Robertson on 26 April 2024, trading 69,000 units of SAVA stock currently worth $1,518,000.
What does Cassava Sciences Inc do?
refer to descriptions included in the company's filings with the securities and exchange commission for more information about the company. the company does not intend to update and does not take responsibility for any information published on linkedin.
What does Cassava Sciences Inc's logo look like?
Complete history of Robert Gussin stock trades at Cassava Sciences Inc
Cassava Sciences Inc executives and stock owners
Cassava Sciences Inc executives and other stock owners filed with the SEC include:
-
Remi Barbier,
Chairman of the Board, President, Chief Executive Officer -
Remi Barbier,
Founder, Chairman, Pres & CEO -
Nadav Friedmann,
Chief Medical and Operating Officer, Director -
Dr. Nadav Friedmann,
Chief Medical Officer & Director -
Eric J. Schoen,
Chief Financial Officer -
Eric Schoen,
Chief Financial Officer -
Sanford Robertson,
Independent Director -
Robert Gussin,
Independent Director -
Patrick Scannon,
Independent Director -
Michael O' Donnell,
Independent Director -
Dr. James W. Kupiec M.D.,
Chief Clinical Devel. Officer -
Dr. Lindsay H. Burns Ph.D.,
Sr. VP of Neuroscience -
Dr. Michael Marsman,
Sr. VP of Regulatory Affairs -
Michael Zamloot,
Sr. VP of Technical Operations -
Dr. George Thornton,
Sr. VP of Technology -
Saira Ramasastry,
Director -
Pierre Gravier,
Director -
Claude Nicaise,
Director -
Robert Christopher Cook,
SVP & General Counsel -
Richard Barry,
Director -
James William Kupiec,
Chief Medical Officer -
Robert Eugene Jr Anderson,
Director